Stock CUBIST PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Cubist Pharmaceuticals Inc

Equities

US2296781071

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cubist Pharmaceuticals Inc
2014 Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug RE
2014 Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market
BU
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
BU
Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.
PR
Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation
BU
Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action
PU
Cubist Pharmaceuticals : Names Dr. Patrick Vink Chief Operating Officer
BU
Cubist Pharmaceuticals : to Present at Jefferies 2014 Healthcare Conference
BU
Cubist Pharmaceuticals : Reports Third Quarter 2014 Financial Results
BU
Cubist Pharmaceuticals : Technical Data on Biotech Equities - Intrexon, Keryx Biopharma, Spectrum Pharma, Sangamo BioSciences, and Cubist Pharma
PR
Cubist Pharmaceuticals : Names Robert J. Perez Chief Executive Officer
BU
Cubist Pharmaceuticals : to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014
BU
Cubist Pharmaceuticals : to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014
BU
Cubist Pharmaceuticals : to Present New Data on Antibiotics Portfolio at IDWeek 2014
BU
Cubist Pharmaceuticals : Announces Continued Global Expansion with Opening of International Headquarters in Zurich
BU
Cubist Pharmaceuticals : to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
BU
Cubist Pharmaceuticals : to Present at Morgan Stanley Global Healthcare Conference
BU
Cubist Pharmaceuticals : Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review
BU
Cubist Pharmaceuticals : Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Following Complaints of Foreign Particulate Matter in Reconstituted Vials
BU
Cubist Pharmaceuticals : Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma, Cubist Pharma, and Idera Pharma
PR
Cubist Pharmaceuticals : Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Cubist Pharmaceuticals Inc
  5. Press Releases